NovaBay Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€4.05M - Cost of goods sold
€1.44M - Gross profit
€2.61M - SG&A expenses
€8.55M - R&D expenses
€11.94K - EBITDA
-€6.29M - D&A
€241.39K - EBIT
-€6.42M - Interest expenses
€192.77K - EBT
-€7.53M - Tax expenses
€0.00 - Net income
€2.84M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€365.92K - Changes in working capital
-€978.34K - Operating cash flow
-€6.17M - Capex
€1.71K - Other investing cash flow
€0.00 - Net investing cash flow
-€914.36K - Total cash dividends paid
€0.00 - Issuance of common stock
€2.24M - Debt repayment
-€247.36K - Other financing cash flow
€2.36M - Net financing cash flow
€1.96M - Foreign exchange effects
€35.82K - Net change in cash
€3.92M - Cash at end of period
€4.97M - Free cash flow
-€6.17M
Balance sheet
- Cash and cash equivalents
€4.56M - Cash and short-term investments
€4.56M - Total receivables
€2.56K - Inventory
€398.33K - Other current assets
€256.74K - Total current assets
€5.22M - Property, plant & equipment
€270.39K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€406.86K - Other non-current assets
€1.71K - Total non-current assets
€678.95K - Total assets
€5.89M - Accounts payable
€515.18K - Short-term debt
€443.53K - Other current liabilities
€664.45K - Total current liabilities
€1.83M - Long-term debt
€445.24K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€445.24K - Total liabilities
€2.27M - Common stock
€49.47K - Retained earnings
-€151.58M - Other equity
€0.00 - Total equity
€3.62M - Total liabilities and shareholders' equity
€5.89M
Company information
- Market capitalization
€3.01M - Employees
13 - Enterprise Value
-€3.86M
Company ratios
- Gross margin
-
64.4% Much better than peer group: -606,610,872,807.0% - EBITDA margin
-
-155.3% Much better than peer group: -2,949,111,539,927.4% - EBIT margin
-
-158.5% Much better than peer group: -2,969,171,162,198.7% - EBT margin
-
-186.0% Much better than peer group: -2,922,062,601,006.4% - Net margin
-
70.0% Much better than peer group: -2,922,062,608,708.4% - ROE
-
78.3% Much better than peer group: -8,508.5% - ROA
-
48.1% Much better than peer group: -224.5% - Asset turnover
-
68.7% Much better than peer group: 19.7% - FCF margin
-
-152.3% Much better than peer group: -2,898,438,398,407.9% - FCF yield
-205.3% - Efficiency ratio
255.3% - Net sales per employee
-
€311.66K - Net income per employee
-
€218.09K